Creative Biolabs provides end-to-end cationic nanoemulsion (CNE) development services for non-clinical mRNA research. Our platform integrates rational lipid-oil core engineering with surface functionalization to enable targeted mRNA delivery to specific tissues—exclusively supporting mechanistic studies in validated preclinical models.
We optimize cationic lipid composition and oil-phase ratios to achieve high mRNA encapsulation efficiency, stable surface charge profiles, and controlled release kinetics for longitudinal expression studies.
We conduct comprehensive validation across primary cell cultures, 3D organoid systems, and murine models, employing multi-omics endpoints including spatial transcriptomics and proteomics to quantify mRNA expression dynamics and functional protein output.
We engineer CNE surfaces with tissue-specific ligands to advance targeted mRNA delivery solutions, including:
| Functionalization | Research Application | Validation Method |
|---|---|---|
| Dendritic Cell Targeting | Vaccine immunology mechanism studies | DC uptake quantification |
| Pulmonary Epithelium Targeting | Lung-specific expression analysis | In vivo IVIS imaging |
| pH-Responsive Release | Tumor microenvironment mRNA activation | Lysosomal escape tracking |
Lipid-based Vector Development
Polymer-based Vector Development
Cationic nanoemulsions (CNEs) function as modular platforms for co-delivering mRNA antigens with immune potentiators, enabling quantitative dissection of germinal center B-cell kinetics and tissue-resident T-cell dynamics in mucosal immunity. Recent advances demonstrate spatial immune profiling capabilities—such as coordinated sIgA production and TRM persistence in pulmonary models—integrated with multi-omics endpoints to deconvolute adaptive immune priming pathways.
Targeted CNEs facilitate delivery of mRNA-encoded editors to neuronal and epithelial systems, supporting functional protein expression studies in cerebral organoids and airway models. These systems validate therapeutic mechanisms like tau clearance and ion channel restoration through transient expression profiling, prioritizing safety evaluation in somatic contexts.
Peptide-functionalized CNEs enable mRNA-mediated investigations of immune checkpoint modulation and pathway kinetics in orthotopic tumors. RGD-modified systems quantify T-cell infiltration via intravital microscopy while monitoring checkpoint dynamics, with glioblastoma models revealing Notch pathway suppression and MDSC reduction through spatial proteomics.
| Application | Core Innovation | Research Value |
|---|---|---|
| Photo-controlled Delivery | Light-triggered endosomal disruption | Spatiotemporal precision for gene circuit studies |
| Mucosal Immunity Platform | TLR agonist-enhanced APC activation | Modeling natural infection immune responses |
| CNS-Targeted Editing | Receptor-mediated transcytosis optimization | BBB penetration mechanism analysis |
| Tumor Immune Modulation | Combinatorial immune potentiator co-delivery | Tumor-immune synapse deconvolution |
| Parameter | Standard LNPs | CNE Platform | Research Value |
|---|---|---|---|
| Lung Expression | <5% total dose | >25% total dose | Enables respiratory disease research |
| Endosomal Escape | 30-40% efficiency | >60% efficiency | Improves functional protein yield |
| Lyophilization Stability | Limited | 4°C stable >30d | Facilitates multi-center studies |
| Immune Profile | High IFN-α induction | Tunable response | Isolate vaccine immunogenicity variables |
Advance your preclinical mRNA research with nano-delivery expertise. Our CNE platform integrates rational lipid-oil engineering with AI-driven design to deliver:
Creative Biolabs pioneers end-to-end cationic nanoemulsion solutions that merge biomaterial innovation with targeted delivery engineering. Our platform empowers researchers to:
By synergizing computational design with empirical validation, we provide non-viral vectors optimized for in vivo mechanism studies—exclusively supporting preclinical research.
A: CNE’s cationic lipid-oil core enables superior mucosal penetration and programmable non-hepatic tropism, facilitating targeted delivery to immune cells and lung/spleen microenvironments without dominant liver sequestration.
A: Our workflow integrates dsRNA removal, tissue-optimized UTR design, and lyophilization protocols to preserve mRNA integrity across primary cells and 3D organoids.
A: We enable mRNA-encoded editor delivery to somatic cells in organoid models, with off-target analysis aligned with NIH guidelines.
A: Standardized microfluidic production and multi-batch physicochemical analytics ensure nanoparticle consistency for longitudinal studies.
A: Projects advance from design to data in 10-16 weeks, including formulation screening and in vitro validation.
Reference
